Preoperative Clinical and Pathological Characteristics of pT0 Prostate Cancer in Radical Prostatectomy by Park, Junsoo et al.
Korean Journal of Urology
Ⓒ The Korean Urological Association, 2010 386 Korean J Urol 2010;51:386-390
www.kjurology.org
DOI:10.4111/kju.2010.51.6.386
Urological Oncology
Preoperative Clinical and Pathological Characteristics of pT0 
Prostate Cancer in Radical Prostatectomy
Junsoo Park, In Gab Jeong, Jeong Kyoon Bang, Young Mee Cho
1, Jae Y. Ro
1,2, Jun Hyuk Hong, 
Hanjong Ahn, Choung-Soo Kim
Departments of Urology and 
1Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, 
2Department of 
Pathology, The Methodist Hospital, Weill Medical College of Cornell University, Huston, TX, USA
Purpose: To analyze the preoperative clinical and pathological characteristics of pa-
tients with pT0 prostate cancer. 
Materials and Methods: We retrospectively reviewed the records of 702 patients who 
underwent radical prostatectomy (RP) at our institution between January 2004 and 
July 2008 for clinically localized prostate cancer. If there was no evidence of residual 
tumor in the pathological specimen of the prostate, a patient was staged as pT0. Patients 
with pT0 disease were compared with a control group of patients who were operated 
on during the same period. 
Results: Overall, 9 (1.3%) patients were staged as pT0 on the pathologic examination. 
Significant differences were observed between the pT0 group and the control patients 
in the biopsy Gleason score (p=0.004), the number of positive cores on biopsy (p=0.018), 
the tumor length of positive cores (p＜0.001), and prostate volume (p=0.015). Cutoff 
values predictive of pT0 tumor status were defined as a biopsy Gleason score sum ≤6, 
2 or fewer positive biopsy cores, tumor length on biopsy ≤2 mm, and prostate volume 
＞30 cm
3. Whereas 8 of the 9 (88.9%) pT0 patients showed all of these characteristics, 
only 55 of the 693 (7.9%) control patients fulfilled the criteria. The combination sug-
gested above afforded a sensitivity of 88.8% and a specificity of 92.1% for the prediction 
of pT0 status. 
Conclusions: The frequency of pT0 prostate cancer seen on RP was 1.3%. A combination 
of clinicopathological features, incorporating a biopsy Gleason score, the number of pos-
itive biopsy cores, tumor length on biopsy, and prostate volume, was useful to predict 
pT0 stage on RP.
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INTRODUCTION
Because of the increased use of screening tests for pros-
tate-specific antigen (PSA), diagnosis of prostate cancer at 
an early clinical stage and small tumor size has recently 
increased, and as a consequence, tumor volume in radical 
prostatectomy (RP) specimens has decreased [1,2]. Patho-
logical stage pT0 is defined as no evidence of residual tumor 
in an RP specimen from a patient in whom biopsy-proven 
prostate carcinoma was histologically diagnosed. This was 
termed the “vanishing cancer phenomenon” by Goldstein 
et al [3]. The pT0 stage of prostate cancer has been observed 
as a result of hormone therapy or prior transurethral re-
section of the prostate (TURP) for benign prostatic hyper-
plasia before RP [2,4-7]. Although much research has ad-
dressed these two scenarios of pT0 stage prostate cancer 
[8-10], patients showing pT0 status in cases other than 
these two scenarios occur very rarely (0.2-0.8% of all pros-
tate cancer patients), and few studies have examined such 
patients [11-13].Korean J Urol 2010;51:386-390
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　The clinical significance of pT0 staging remains unclear. 
However, several reports indicate that pT0 stage patients 
show a highly satisfactory clinical outcome [12,13]. In a 
10-year follow-up study of 38 pT0 patients, neither re-
currence nor progression was observed in any patient. 
Therefore, to prevent unnecessary treatment of such clin-
ically insignificant cancers, it is essential to identify pre-
operative clinical and pathologic characteristics that help 
to detect patients with a high probability of pT0 staging on 
RP specimens.
　Because the pT0 stage of prostate cancer is rarely ob-
served, only a few studies of the preoperative features of 
such patients have appeared [3,11,12,14]. Moreover, there 
are few reports on the characteristics of pT0 Asian patients. 
It has been reported that, compared to Western countries, 
Asian populations show a lower incidence of prostate can-
cer, but that Asians have high-grade prostate cancer 
(Gleason score above 7) and a smaller prostate volume 
[15-17]. Thus, considering this ethnic difference, simple 
adaptation of the predictive measures of prostate cancer 
pT0 stage used in Western countries to Asian populations 
may be inappropriate. Therefore, in the present study, we 
analyzed preoperative clinical and pathologic character-
istics of patients in whom pT0 staging was confirmed after 
diagnosis of prostate cancer on prostate needle biopsy and 
RP. Patients who underwent hormone therapy or who were 
diagnosed with prostate carcinoma when receiving TURP 
for benign prostatic hyperplasia before RP were not in-
cluded in this study.
MATERIALS AND METHODS
We analyzed 702 patients with prostate cancer who under-
went RP at our institution between January 2004 and July 
2008. Those who received preoperative hormone treat-
ment (68 cases) or who were diagnosed with prostate carci-
noma by TURP for benign prostatic hyperplasia before RP 
(13 cases) were excluded from the analysis. All patients had 
clinically localized prostate cancer by digital rectal exami-
nation, endorectal ultrasonography, and magnetic reso-
nance imaging (MRI). All patients underwent retropubic 
RP and pelvic lymph node dissection. We re-examined and 
retrospectively analyzed the following clinicopathological 
factors: age, PSA level, digital rectal examination result, 
Gleason score, number and length of positive cores in the 
prostate needle biopsy, and tumor volume of the RP 
specimen. The pathological pT0 stage was assigned when 
no residual tumor was seen in the RP specimen.
　Each RP specimen, which was examined by two genito-
urinary (GU) pathology specialists at our institution, was 
completely fixed and cut into 3 mm slices. When areas with 
possible prostate cancer were observed, these regions were 
examined by immunochemical staining using AMACR 
(1:40; BIOCARE, Walnut Creek, USA) and anti-p63 (1:100; 
DAKO, Glostrup, Denmark). Prostate needle biopsy tissue 
was reexamined only when residual tumor was not 
observed. When prostate cancer was nevertheless detected 
in the biopsy during reexamination, the RP tissue block cor-
responding to the tumor area of the biopsy was serially sec-
tioned and the block was turned upside down to create more 
serial sections. Slides were screened by pathology fellows 
or residents and were further examined for cancer by the 
two GU pathology specialists. In brief, all RP specimens of 
stage pT0 were examined by at least three pathologists. 
　Patients with pT0 stage prostate cancer were compared 
with a control group consisting of the remaining 693 pros-
tate cancer patients treated at our institution during the 
same period. Preoperative clinical and pathologic charac-
teristics including age, PSA level, digital rectal examina-
tion data, Gleason score, the number and length of positive 
cores on prostate needle biopsy, prostate volume on endor-
ectal ultrasonography, and tumor size of the RP specimen 
were examined in all patients. Prostate volume was eval-
uated by using the ellipsoid formula, π/6 x prostate width
x height x depth. These features were analyzed in a search 
for characteristics predictive of the pT0 stage of prostate 
cancer. We calculated the cutoff value of clinicopatho-
logical factors significantly correlated with pT0 staging 
and also investigated the sensitivity and specificity of such 
factors. To compare patients with pT0 prostate cancer with 
the control group, the chi-square test was used to analyze 
categorical variables (digital rectal examination), and the 
Mann-Whitney U test was used when consecutive varia-
bles (age, preoperative PSA level, number and length of 
positive cores on preoperative needle biopsy, Gleason score 
on needle biopsy) were examined. p-values of ＜0.05 were 
considered to reflect a statistically significant difference. 
SPSS, version 12.0, was used for all statistical analyses 
(SPSS Inc., Chicago, IL, USA).
RESULTS
In the present study, 9 (1.3%) of the 702 patients were post-
operatively diagnosed with prostate cancer of pT0 stage. 
The mean age of the nine patients was 66.4 years (range, 
61-73 years), and their average PSA level was 8.1 ng/ml 
(range, 5.0-24.4 ng/ml). Of the nine patients, six (66.7%) 
were of clinical stage T1c, and three (33.3%) were of stage 
T2. Eight patients (88.9%) had a biopsy Gleason score of 6 
and one patient a score of 7 (4＋3). Among the eight (88.9%) 
patients who had two or fewer positive biopsy cores, seven 
had only one positive core. The other patient had two pos-
itive cores. The mean length of the positive biopsy cores was 
3 mm (range, 1.0-14.0 mm). Except for the one patient in 
whom tumor length was 14 mm and the one patient in 
whom tumor length was unknown, a tumor size of 2 mm 
or less was found in the remaining seven patients. The 
mean prostate volume was 54.1 cm
3 (range, 23-82 cm
3), 
and, except for one patient (volume, 23 cm
3), the prostate 
volume of all pT0 patients was at least 30 cm
3. Of the nine 
patients, four had high-grade prostatic intraepithelial neo-
plasia (HGPIN) (Table 1). During the mean follow-up peri-
od of 23.6 months, no biochemical recurrence occurred in 
any patient.Korean J Urol 2010;51:386-390
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TABLE 1. Characteristics of nine pT0 patients
Clinical data Biopsies HGPIN 
in RP 
specimen
Patient 
number
Age
(years)
Clinical
stage
PSA
(ng/ml)
Prostate 
volume (cm
3)
Gleason
score
P/T
Length of 
cancer (mm)
Location
1 61 T2 5 68 6 1/8 1 Left  postero-lateral Yes
2 71 T1c 8 82 6 1/12 1 Right  postero-lateral No
3 71 T1c 5.9 23 7 4/13 14 Both postero lateral No
4 61 T2 7.2 36 6 1/12 1 Left apical No
5 73 T1c 6.2 36 6 1/12 2 Right apical Yes
6 67 T2 5.6 65 6 2/17 2 Right postero lateral Yes
7 65 T1c 5 80 6 1/12 1 Left  midline Yes
8 68 T1c 24.4 35 6 1/12 1 Right postero lateral No
9 61 T1c 5.2 63 6 1/12 1 Left No
PSA: prostate-specific antigen, P/T: positive/total cores, HGPIN: high grade prostatic intraepithelial neoplasia, RP: radical prostatec-
tomy
TABLE 2. Comparisons between the pT0 group and the control group
pT0 group (n=9) Control group (n=693) p-value
Mean age (year)±SD 66.4±4.7 (61-73) 65.0±6.6 (41-79) 0.500
Mean preoperative PSA (ng/ml)±SD 8.1±6.2 (5.0-24.4)  11.2±12.5 (3.2-162) 0.447
Abnormal DRE rate (%) 33.3 38.3 0.464
Gleason score on biopsy (≤6/＞6, %) 88.9/11.1 53.3/46.7 0.042
No. of positive cores (≤2/＞2, %) 88.9/11.1 48.4/51.6 0.018
Tumor length on biopsy (≤2/＞2 mm, %) 88.9/11.1 23.0/77.0 ＜0.001
Mean prostate volume (cm
3)±SD 54.1±21.8 (23-82) 37.5±20.1 (8-275) 0.015
SD: standard deviation, PSA: prostate-specific antigen, DRE: digital rectal examination
TABLE 3. Number of patients satisfying the four characteristics
pT0 
patients
Control 
group
Total
4 criteria combined
4 criteria not combined
8
1
  55
638
  63
639
Total 9 693
4 criteria, Preoperative Gleason score ≤6, Number of positive cores
≤2, Tumor length on biopsy ≤2 mm, Prostate volume ≥30 cm
3
　In a comparison between the two groups (the 9 patients 
with pT0 staging and the remaining 693 patients with tu-
mors seen in RP specimens), no significant differences were 
found in mean age (66.4 vs. 65.0 years, p=0.500), PSA level 
(8.1 vs. 11.2 ng/ml, p=0.447), or abnormality in the digital 
rectal examination (33.3% vs. 38.3%, p=0.464). However, 
a significant difference was found when preoperative biop-
sy Gleason score was examined (≤6/＞6; 88.9/11.1% in 
those with pT0 disease vs. 53.3/46.7% in the control group, 
p=0.042). Another significant difference was that two or 
fewer positive cores were seen in patients with pT0 staging 
(88.9% in pT0 disease vs. 48.4% in the control group, 
p=0.018). The size of the tumor on biopsy also differed sig-
nificantly between the two groups. It was 2 mm or less in 
length in 88.9% of those with pT0 disease vs. 23.0% of the 
control group (p＜0.001). Lastly, the mean prostate volume 
was 54.1 cm
3 in pT0 patients but 37.5 cm
3 in the control 
group, showing that pT0 patients had a larger prostate vol-
ume (p=0.015) (Table 2). 
　For predicting pT0 staging of prostate cancer, we choose 
four criteria such as a Gleason score of 6 or less, two or fewer 
positive cores, a tumor size of 2 mm or less on preoperative 
biopsy, and a prostate volume of 30 cm
3. Combining the four 
criteria showed a sensitivity of 88.8%, a specificity of 93.4%, 
a positive predictive value of 12.7%, and a negative pre-
dictive value of 99.8% (Table 3). In Table 4, previous studies 
in the literature on the incidence and characteristics of pT0 
stage patients are reviewed and compared with our results.
DISCUSSION
Previous studies have found that, after patients who re-
ceived preoperative hormone therapy and who were diag-
nosed with prostate cancer when undergoing TURP for 
treatment of benign prostatic hyperplasia were excluded, 
the incidence of pT0 staging after RP was extremely low 
(0.2-0.8%) [11-13,18]. Several explanations are possible for 
patients being staged as pT0 after RP. First, the tumor may 
have been completely removed during the preoperative 
biopsy. A very small tumor may have been eliminated dur-Korean J Urol 2010;51:386-390
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TABLE 4. Literature review
No. 
of patients
Study 
period
Race 
Incidence 
(%)
Predictor of pT0 
prostate cancer
Bostwick and Bostwick
 [11], 2004
6,843 1966-1995 Caucasian (American) 0.6 Not identified
Descazeaud et al [12], 2006 1,950 1996-2005 Caucasian (French) 0.5 Gleason score ＜7
Positive biopsy core ≤1
Tumor length on biopsy ＜2 mm
Prostate weight ＞60 g 
Herkommer et al [13], 2004 3,609 1990-2003 Caucasian (German) 0.8 Not identified
Bessede et al [18], 2010 7,693 1998-2006 Caucasian (French) 0.4 Not identified
Present study 702 2004-2008 Asian (Korean) 1.3 Gleason score ≤6
Positive biopsy cores ≤2
Tumor length on biopsy ≤2 mm
Prostate volume ＞30 cm
3
ing specimen workup procedures, such as paraffin block 
preparation. Second, the preoperative biopsy may have 
yielded a false-positive result. Such false-positives can 
arise as a result of pathologist error. Third, the pathological 
examination of an RP specimen may have resulted in a 
false-negative finding due to a very small tumor volume, 
in which the tumor could be easily undetected by the path-
ologist, or due to an inflammatory reaction. Finally, speci-
men mix-up or a mislabeled specimen may result in a 
false-positive diagnosis of prostate cancer. DNA identity 
testing is available and could be used if the original diag-
nostic material is available [14].
　Indeed, pathological examination plays an important 
role in diagnosing small tumors. In a study by Kollermann 
and colleagues, in which four GU pathology experts re-
examined RP specimens from 20 pT0 patients, small re-
sidual tumors (≤0.2 ml in volume) were discovered in 13 
patients [9]. In the present study, after fixation, whole 
specimens were cut into 3 mm slices, and when no tumor 
was found in these initial sections, additional tissue slides 
were prepared. Absence of residual tumor was confirmed 
by at least two GU pathology specialists. 
　Whereas the incidence of pT0 staging is generally known 
to be under 1%, the frequency was 1.3% in the present study 
[11-13]. Most pT0 stage patients in our study had PSA lev-
els less than 10 ng/ml, initial prostate needle biopsies with 
a Gleason score of 6 or less, two or fewer positive cores, a 
core length of 2 mm or less, and larger tumor volume. 
Descazeaud et al examined 11 patients who were diag-
nosed as pT0 stage after RP and reported that 90.9% of the 
patients had PSA levels less than 15 ng/ml, 81.8% had one 
positive core, and all had a Gleason score of 6 or less [12]. 
The pT0 stage group also showed a significant difference 
from the control group in prostate weight (72 g vs. 51 g). 
Given that a small tumor is more difficult to find in a 
large-volume prostate, the frequency of pT0 staging after 
RP may be associated with prostate volume. In our analysis 
of preoperative characteristics in the two groups, a sig-
nificant difference was found in those with a Gleason score 
of 6 or less, two or fewer positive cores, and core length of 
2 mm or less. Also, four patients had HGPIN in the RP 
specimen. Mean prostate volume was also significantly 
larger in patients with pT0 staging than in the control 
group. Given that the prostate volume of Asians is smaller 
than that of Westerners, application of Western pT0 stag-
ing-predictive factors for prostate cancer to Asian pop-
ulations is clearly inappropriate. 
　The use of RP for the treatment of pT0 prostate cancer 
is controversial; it is unclear whether RP is appropriate or 
excessive. In a study on patients diagnosed with T1a pros-
tate cancer after TURP, Epstein et al claimed that a trace 
of disease progression within 8 years was found in only 16% 
of patients [19]. However, according to Carter et al, ad-
vanced prostate cancer was detected after RP in 6% of T1a 
prostate cancer specimens and 32% of T1b specimens [20]. 
It is evident that characteristics predictive of preoperative 
pT0 staging would be helpful in deciding whether defini-
tive treatment should be immediately implemented or 
whether watchful waiting might be more appropriate.  
　In our analysis of the features predictive of pT0 staging 
after RP, the combination of a Gleason score of 6 or less, two 
or fewer positive cores, a positive core length of 2 mm or less, 
and a prostate volume of 30 cm
3 or larger offered a sensi-
tivity and a specificity of 87.5% and 93.1%, respectively. In 
the control group, all patients identified by these criteria 
had low-grade pT2 prostate cancer (Gleason score of 6 or 
less). 
　Few studies on the characteristics predictive of pT0 stage 
after RP have appeared. Our study is particularly mean-
ingful in that it is the first attempt to analyze features pre-
dictive of pT0 staging in an Asian population. However, the 
most notable limitation of our study is the extremely low 
incidence of pT0 staging after RP. This low incidence is in-
sufficient for the multiple logistic regression model that is 
required to investigate the predictive factors of pT0 stage 
after RP as in a previous study [12]. Furthermore, data on 
the free/total PSA ratio and PSA velocity were not available 
in our study, so these variables were not analyzed as pre-
dictive factors of pT0 staging after prostatectomy. Hence, 
further multicenter research on the value of these pre-Korean J Urol 2010;51:386-390
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dictive characteristics is required.
CONCLUSIONS
In our study of 702 patients who underwent RP after being 
diagnosed with prostate carcinoma by biopsy, the rate of 
pT0 staging was 1.3%. We found that Gleason score, the 
number of positive cores, the positive core length, and the 
prostate volume were helpful in predicting pT0 staging of 
prostate cancer in RP specimens. Considering the favor-
able outcomes of patients with pT0 prostate cancer, these 
predictive factors for pT0 prostate cancer will be useful for 
clinicians and patients when they decide on a treatment.
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